HDFC Pharma and Healthcare Fund(IDCW Reinvest)
Ticker: mf15571
Decent
68/100
☆ Add to Watchlist
More Options
S
SBI Income Plus Arbitrage Active FOF(IDCW)
The fund shows potential but is hindered by inconsistent growth and moderate profitability metrics. Caution is advised.
View details
S
SBI Income Plus Arbitrage Active FOF(IDCW Payout)
The fund shows decent potential but lacks strong growth drivers and consistency in profitability.
View details
L
LIC MF Banking & PSU Fund(W-IDCW)
The LIC MF Banking & PSU Fund shows decent potential with stable growth prospects, but investors should be cautious of execution risks and governance issues.
View details
L
LIC MF Banking & PSU Fund(M-IDCW)
The LIC MF Banking & PSU Fund shows decent potential with stable growth and profitability metrics, but some risks in governance and execution need to be monitored.
View details
L
LIC MF Banking & PSU Fund(DD-IDCW)
The LIC MF Banking & PSU Fund shows decent potential with stable growth prospects, but investors should be cautious of execution risks and liquidity issues.
View details
B
Bandhan Large Cap Fund(IDCW Reinvest)
The fund shows decent potential with some growth opportunities, but risks related to execution and liquidity should be monitored.
View details
B
Bandhan Large Cap Fund(IDCW)
The Bandhan Large Cap Fund shows potential with decent growth and profitability metrics, but some risks in governance and execution need to be monitored.
View details
F
Franklin India Technology Fund(IDCW)
The fund shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
F
Franklin India Technology Fund(IDCW Payout)
The fund shows decent potential for growth with manageable risks, making it a reasonable investment option.
View details
K
Kotak Special Opportunities Fund(IDCW)
The Kotak Special Opportunities Fund shows decent potential with consistent growth and profitability metrics, but some valuation concerns and execution risks should be monitored.
View details
K
Kotak Special Opportunities Fund(IDCW Payout)
The Kotak Special Opportunities Fund shows decent potential with moderate growth and profitability metrics, but faces challenges in valuation and execution risks.
View details
M
Mirae Asset Balanced Advantage Fund(IDCW)
The fund shows decent potential with a balanced approach to risk and growth, but investors should remain cautious of execution risks.
View details
B
Bank of India Small Cap Fund(IDCW)
The Bank of India Small Cap Fund presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
K
Kotak Multi Asset Omni FOF(IDCW Payout)
The Kotak Multi Asset Omni FOF shows decent potential with moderate growth and profitability metrics, but faces challenges in valuation and execution risks.
View details
K
Kotak Multi Asset Omni FOF(IDCW)
The Kotak Multi Asset Omni FOF shows decent potential but carries some risks that investors should consider.
View details
H
HSBC CRISIL IBX 50:50 Gilt Plus SDL Apr 2028 Index Fund(IDCW)
The fund is a decent option for conservative investors seeking stability in fixed income, but lacks growth potential.
View details
Business Overview
HDFC Pharma and Healthcare Fund is a dedicated mutual fund focusing on the dynamic pharmaceutical and healthcare sectors. Ideal for investors seeking growth through exposure to India's robust healthcare landscape, this fund aims to capitalize on the increasing demand for healthcare services and innovations. With a strong management team and a strategic investment approach, it offers potential for long-term wealth creation.
- Focuses on pharmaceutical and healthcare sectors
- Ideal for growth-oriented investors
- Benefits from India's healthcare demand surge
- Managed by experienced professionals
- Potential for long-term capital appreciation
Investment Thesis
HDFC Pharma and Healthcare Fund presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital healthcare services, and attractive valuation compared to peers. This fund is well-positioned to capitalize on the booming healthcare sector in India.
- Backed by HDFC's reputable and experienced management team.
- Increasing demand for digital healthcare solutions offers substantial growth opportunities.
- Valuation metrics indicate the fund is attractively priced relative to industry peers.
- Focus on high-quality pharmaceutical and healthcare companies ensures robust portfolio performance.
- Potential for long-term capital appreciation as the healthcare sector expands.
Opportunity vs Risk
Opportunities
- Strong growth in healthcare sector
- Rising demand for pharmaceuticals
- Government support for healthcare initiatives
- Diversified portfolio of healthcare stocks
Risks ⚠️
- Regulatory changes affecting pharma
- Market volatility impacting returns
- High competition in healthcare space
- Dependency on key pharmaceutical companies
Peer Perspective
HDFC Pharma and Healthcare Fund trades at a slight premium compared to peers like SBI Healthcare Opportunities Fund and ICICI Prudential Pharma Fund. A sustained improvement in margin stability could trigger a rerating.
📊 Stock Investment Checklist (100 Points)
HDFC Pharma and Healthcare Fund(IDCW Reinvest) • Updated: 2025-10-01 02:58:37
-
10BusinessHighPharma sector is future-ready with strong growth potential.
-
10GrowthHighConsistent revenue growth observed over the past few years.
-
10ProfitabilityHighROE and ROCE are above industry averages, indicating strong profitability.
-
8ValuationHighP/E and P/B ratios are reasonable compared to peers.
-
7BalanceHighDebt levels are manageable with good liquidity.
-
6GovernanceGoodPromoter holding is strong, with minimal pledging.
-
5DriversGoodGrowth catalysts present, but execution risks remain.
-
5TechnicalsGoodMarket sentiment is neutral with moderate liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
The fund shows decent potential with strong fundamentals in the pharma sector, but investors should be cautious of execution risks.